Cognition Therapeutics, Inc.

NasdaqGM:CGTX Stock Report

Market Cap: US$26.9m

Cognition Therapeutics Management

Management criteria checks 1/4

Cognition Therapeutics' CEO is Lisa Ricciardi, appointed in Mar 2020, has a tenure of 4.75 years. total yearly compensation is $1.66M, comprised of 35.3% salary and 64.7% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $47.76K. The average tenure of the management team and the board of directors is 1.8 years and 3.8 years respectively.

Key information

Lisa Ricciardi

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage35.3%
CEO tenure4.8yrs
CEO ownership0.2%
Management average tenure1.8yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely

Dec 20
Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely

Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Sep 06
Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease

Jul 31

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

May 22
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Apr 18

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Nov 30
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Aug 15
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Mar 17
Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

Sep 27

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Aug 12
We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

Aug 05

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Mar 19
We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

CEO Compensation Analysis

How has Lisa Ricciardi's remuneration changed compared to Cognition Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$34m

Jun 30 2024n/an/a

-US$31m

Mar 31 2024n/an/a

-US$29m

Dec 31 2023US$2mUS$587k

-US$26m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$24m

Dec 31 2022US$1mUS$550k

-US$21m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$22m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$11mUS$409k

-US$16m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020US$1mUS$287k

-US$12m

Compensation vs Market: Lisa's total compensation ($USD1.66M) is above average for companies of similar size in the US market ($USD651.40K).

Compensation vs Earnings: Lisa's compensation has increased whilst the company is unprofitable.

CEO

Lisa Ricciardi (64 yo)

4.8yrs

Tenure

US$1,660,686

Compensation

Ms. Lisa R. Ricciardi serves as Chief Executive Officer and President at Cognition Therapeutics, Inc. since March 2020 and serves as Director since March 2019. She serves as a Consultant of Davita RX. Ms....

Leadership Team

NamePositionTenureCompensationOwnership
Lisa Ricciardi
CEO, President & Director4.8yrsUS$1.66m0.18%
$ 47.8k
John Doyle
Chief Financial Officer1.6yrsUS$737.26k0.045%
$ 12.2k
Anthony Caggiano
Chief Medical Officer and Head of R&D5.7yrsUS$972.12k0.045%
$ 12.1k
Steven Weissman
VP & Head of CMC1.4yrsno datano data
Anita Cornet
Head of Qualityless than a yearno datano data
Bobby Horn
Corporate Controller1.9yrsno datano data

1.8yrs

Average Tenure

54yo

Average Age

Experienced Management: CGTX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Lisa Ricciardi
CEO, President & Director5.8yrsUS$1.66m0.18%
$ 47.8k
Ellen Richstone
Independent Director3.1yrsUS$83.61k0.039%
$ 10.4k
Jack Khattar
Independent Chairman of the Board4.4yrsUS$145.11k0.014%
$ 3.9k
Harry LeVine
Member of Scientific Advisory Boardno datano datano data
Susan Catalano
Member of Scientific Advisory Board2.9yrsno datano data
Cynthia Lemere
Member of Scientific Advisory Boardno datano datano data
Michael Grundman
Member of Medical Advisory Board2.9yrsno datano data
Aaron Glenn Fletcher
Independent Director9.4yrsUS$74.61k0.014%
$ 3.9k
John Cirrito
Member of Scientific Advisory Boardno datano datano data
Rolf Craven
Member of Scientific Advisory Boardno datano datano data
Alison Goate
Member of Scientific Advisory Boardno datano datano data
Robert Mach
Member of Scientific Advisory Boardno datano datano data

3.8yrs

Average Tenure

63yo

Average Age

Experienced Board: CGTX's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 07:38
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cognition Therapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
null nullB. Riley Securities, Inc.
Daniil GataulinChardan Capital Markets, LLC